NRSN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is 8.25 USD with a low forecast of 7.50 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.866

Low

7.50

Averages

8.25

High

9.00

Current: 0.866

Low

7.50

Averages

8.25

High

9.00

Noble Capital

Robert LeBoyer

initiated

2025-10-14

Reason

Noble Capital

Robert LeBoyer

Price Target

2025-10-14

initiated

Reason

Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense with an Outperform rating and $9 price target. Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer's disease showed "promising data."

D. Boral Capital

Jason Kolbert

Buy

initiated

$14

2025-05-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14

2025-05-12

initiated

Buy

Reason

Maxim Group

Naz Rahman

Strong Buy

Hold

Downgrades

n/a

2024-12-16

Reason

Maxim Group

Naz Rahman

Price Target

n/a

2024-12-16

Downgrades

Strong Buy

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Neurosense Therapeutics Ltd (NRSN.O) is -2.88, compared to its 5-year average forward P/E of -2.09. For a more detailed relative valuation and DCF analysis to assess Neurosense Therapeutics Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.09

Current PE

-2.88

Overvalued PE

-1.08

Undervalued PE

-3.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.30

Current PS

62.43

Overvalued PS

45.42

Undervalued PS

-22.83

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NRSN News & Events

Events Timeline

No data

News

3.5

12-04PRnewswire

NeuroSense Resumes Regulatory Progress for PrimeC in Canada, Anticipates NDS Submission by Mid-2026

4.0

11-24Benzinga

D. Boral Capital Reiterates Buy Rating for NeuroSense Therapeutics with $14 Price Target Intact

9.0

11-24PRnewswire

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

People Also Watch

Frequently Asked Questions

What is Neurosense Therapeutics Ltd (NRSN) stock price today?

The current price of NRSN is 0.8655 USD — it has decreased -2.7 % in the last trading day.

What is Neurosense Therapeutics Ltd (NRSN)'s business?

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

What is the price predicton of NRSN Stock?

What is Neurosense Therapeutics Ltd (NRSN)'s revenue for the last quarter?

Neurosense Therapeutics Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Neurosense Therapeutics Ltd (NRSN)'s earnings per share (EPS) for the last quarter?

Neurosense Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Neurosense Therapeutics Ltd (NRSN)'s fundamentals?

The market is revising No Change the revenue expectations for NeuroSense Therapeutics Ltd. (NRSN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -25.39%.

How many employees does Neurosense Therapeutics Ltd (NRSN). have?

Neurosense Therapeutics Ltd (NRSN) has 15 emplpoyees as of December 15 2025.

What is Neurosense Therapeutics Ltd (NRSN) market cap?

Today NRSN has the market capitalization of 26.43M USD.